Skip to main content

Table 2 Clinical parameters of the first proband after GH treatment

From: Molecular genetic analysis and growth hormone response in patients with syndromic short stature

CA (year) BA (year) Height (cm) Weight (kg) GH (mg/kg/w) IGF-1 ng/mL HbA1c (3.6–6.0%) INS (2.6–11.8 µU/mL) T3 (nmol/L) T4 (nmol/L) FT3 (pmol/L) FT4 (pmol/L) TSH (mIU/L)
4–3/12 2.5 85.8 (− 5.05SD) 13.8 (− 1.74SD) 0.2 88.9 (49–283) 4.7 1.8 3.0 (1.4–3.8) 120.3 (76.6–189.0) 7.1 (3.7–8.5) 17.8 (12.3–22.8) 2.91 (0.7–5.97)
4–4/12   86.8 (− 4.93SD) 13.0 (− 2.38SD) 0.2 124 (49–283) 5.2 / 3.4 (1.4–3.8) 145.9 (76.6–189.0) 7.9 (3.7–8.5) 21.0 (12.3–22.8) 2.95 (0.7–5.97)
4–6/12   87.1 (− 5.07SD) 14.0 (− 1.86SD) 0.2 93.9 (49–283) 4.8 4.0 3.1 (1.4–3.8) 112.1 (76.6–189.0) 8.1 (3.7–8.5) 18.3 (12.3–22.8) 2.72 (0.7–5.97)
4–9/12 3 90.0 (− 4.71SD) 40.5 (− 1.81SD) 0.2 107 (49–283) 5.2 2.7 2.9 (1.4–3.8) 142.2 (76.6–189.0) 6.7 (3.7–8.5) 20.1 (12.3–22.8) 2.30 (0.7–5.97)
5   92.4 (− 4.42SD) 16.95 (− 0.67SD) 0.2 245 (50–286) 4.5 2.9 3.4 (1.4–3.8) 123.8 (76.6–189.0) 8.2 (3.7–8.5) 19.2 (12.3–22.8) 4.19 (0.7–5.97)
5–4/12 4 93.4 (− 4.59SD) 16.0 (− 1.44SD) 0.2 291↑ (50–286) 5.3 4.9 3.2↑ (1.3–3.1) 154.9 (66.0–181.0) 8.1 (3.0–9.1) 22.4↑ (12.0–22.0) 1.93 (0.27–4.2)
5–7/12   95.3 (− 4.46SD) 17.5 (− 0.93SD) 0.3 149 (50–286) 5.1 2.1 3.3↑ (1.3–3.1) 157.0 (66.0–181.0) 8.3 (3.0–9.1) 23.1↑ (12.0–22.0) 3.21 (0.27–4.2)
5–10/12 4.5 97.5 (− 4.19SD) 18.0 (− 0.88SD) 0.3 473↑ (50–286) 5.3 9.1 3.6 (1.3–3.1) 171.4 (66.0–181.0) 8.3 (3.0–9.1) 27.2↑ (12.0–22.0) 1.46 (0.27–4.2)
6–1/12   99.6 (− 3.96SD) 19.0 (− 0.65SD) 0.2 416↑ (52–297) 5.1 5.6 3.7 (1.3–3.1) 148.0 (66.0–181.0) 8.6 (3.0–9.1) 22.1↑ (12.0–22.0) 1.61 (0.27–4.2)
6–4/12 5 100.4 (− 4.02SD) 18.0 (− 1.25SD) 0.2 304 (52–297) 5.1 4.2 3.2↑ (1.3–3.1) 128.7 (66.0–181.0) 7.7 (3.0–9.1) 19.4 (12.0–22.0) 1.87 (0.27–4.2)
  1. T3 triiodothyronine, T4 thyroxine, FT3 free triiodothyronine, FT4 free thyroxine, TSH thyroid-stimulating hormone